New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
Recruiting
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: NYU Langone, New York, New York
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Evaluating a Noise Reduction Algorithm With Cochlear Implant Users
Recruiting
In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/30/2024
Locations: Tisch Hospital, New York, New York
Conditions: Hearing Impairment
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Recruiting
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Bladder Cancer
A Study of Pasireotide in People With Prolactinoma
Recruiting
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York
Conditions: Prolactin-Producing Pituitary Tumor
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Mount Sinai, New York, New York
Conditions: HNSCC
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Recruiting
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack, New York
Conditions: Squamous Cell Lung Cancer
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York
Conditions: Prediabetic State, Atherosclerosis, Metformin
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
Recruiting
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/27/2024
Locations: Cold Springs Harbor Laboratory (Specimen Analysis), Cold Spring Harbor, New York
Conditions: Pancreatic Ductal Adenocarcinoma
R-MVST Cells for Treatment of Viral Infections
Recruiting
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Columbia University, New York, New York
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes
Recruiting
Cigarette smoking is now the leading killer of people with HIV (PWH) in the US, and most cessation strategies tried to date have failed to increase long-term quit rates. An "all or none" approach to smoking cessation in PWH offers little benefit to the large majority of PWH who are unable or unwilling to quit. In this proposal we argue that a harm reduction approach (i.e. cut down, get screened for lung cancer, control your blood pressure and cholesterol) has the potential to yield significant b... Read More
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
12/24/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Hiv, Tobacco Use
Central Line Study
Recruiting
Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/24/2024
Locations: Montefiore, Bronx, New York
Conditions: Shock